Faron Pharmaceuticals Limited (AIM:FARN) will hold a capital markets day on October 22 to update investors, analysts, and media on its latest developments. The event will feature presentations from Faron’s CEO, Dr. Juho Jalkanen, and other key speakers, including Dr. Mika Kontro, who will present new data from the BEXMAB clinical trial. The agenda will cover Faron’s strategy, its focus on immunotherapies, and market insights into treating cancers like myelodysplastic syndromes (MDS) and solid tumours. The event will conclude with a Q&A session.
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com